Biomarkers of immediate drug hypersensitivity.
biomarker
drug
hypersensitivity
immediate
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
revised:
29
09
2023
received:
13
04
2023
accepted:
17
10
2023
medline:
10
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
aheadofprint
Résumé
Immediate drug hypersensitivity reactions (IDHRs) are a burden for patients and the health systems. This problem increases when taking into account that only a small proportion of patients initially labelled as allergic are finally confirmed after an allergological workup. The diverse nature of drugs involved will imply different interactions with the immunological system. Therefore, IDHRs can be produced by a wide array of mechanisms mediated by the drug interaction with specific antibodies or directly on effector target cells. These heterogeneous mechanisms imply an enhanced complexity for an accurate diagnosis and the identification of the phenotype and endotype at early stages of the reaction is of vital importance. Currently, several endophenotypic categories (type I IgE/non-IgE, cytokine release, Mast-related G-protein coupled receptor X2 (MRGPRX2) or Cyclooxygenase-1 (COX-1) inhibition and their associated biomarkers have been proposed. A precise knowledge of endotypes will permit to discriminate patients within the same phenotype, which is crucial in order to personalise diagnosis, future treatment and prevention to improve the patient's quality of life.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Institute of Health 'Carlos III' (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)
ID : PI20/01734
Organisme : Institute of Health 'Carlos III' (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)
ID : PI22/01119
Organisme : Institute of Health 'Carlos III' (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)
ID : REI-RICORSRD21/0002/0008 and RD21/0002/0058
Organisme : Andalusian Regional Ministry of Health
ID : PI-0076-2019
Organisme : Andalusian Regional Ministry of Health
ID : PI-0127-2020
Organisme : Andalusian Regional Ministry of Health
ID : PI-0129-2021
Organisme : Andalusian Regional Ministry of Health
ID : PI21/00329
Organisme : Andalusian Regional Ministry of Health
ID : RH-0099-2020(co-fundedbyEuropeanSocialFund)
Organisme : Andalusian Regional Ministry of Health
ID : RC-0004-2021
Organisme : ISCIII thorough AES 2019 within the ERANET-EuroNanoMed-III framework (DrNanoDall project)
ID : AC19/00082
Organisme : Flemish Research Council
ID : 1804523N
Informations de copyright
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71(8):1103-1134.
Stone CA Jr, Trubiano J, Coleman DT, Rukasin CRF, Phillips EJ. The challenge of de-labeling penicillin allergy. Allergy. 2020;75(2):273-288.
Sacco KA, Bates A, Brigham TJ, Imam JS, Burton MC. Clinical outcomes following inpatient penicillin allergy testing: a systematic review and meta-analysis. Allergy. 2017;72(9):1288-1296.
Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-437.
Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-1471.
Castells MC. Drug allergy: phenotypes, endotypes, and biomarkers. J Allergy Clin Immunol Pract. 2017;5(3):626-627.
Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med. 2019;381(24):2338-2351.
Jakubovic BD, Vecillas LL, Jimenez-Rodriguez TW, Sanchez-Sanchez S, Castells M. Drug hypersensitivity in the fast lane. Ann Allergy Asthma Immunol. 2020;124(6):566-572.
Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137(6):1674-1680.
Chompunud Na Ayudhya C, Ali H. Mas-related G protein-coupled receptor-X2 and its role in non-immunoglobulin E-mediated drug hypersensitivity. Immunol Allergy Clin North Am. 2022;42(2):269-284.
Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol. 2016;171(3-4):166-179.
Bavbek S, Pagani M, Alvarez-Cuesta E, et al. Hypersensitivity reactions to biologicals: an EAACI position paper. Allergy. 2022;77(1):39-54.
Jakubovic BD, Sanchez-Sanchez S, Hamadi S, Lynch DM, Castells M. Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association. Allergy. 2021;76(5):1571-1573.
McNeil BD. MRGPRX2 and adverse drug reactions. Front Immunol. 2021;12:676354.
Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75(3):561-575.
Lepelley M, Khouri C, Lacroix C, Bouillet L. Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database. J Allergy Clin Immunol Pract. 2020;8(7):2406-2408 e1.
Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347(8):621-622.
Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol. 2022;62(3):432-448.
Sala-Cunill A, Cardona V. Biomarkers of anaphylaxis, beyond tryptase. Curr Opin Allergy Clin Immunol. 2015;15(4):329-336.
Fernandez-Santamaria R, Ariza A, Fernandez TD, et al. Advances and highlights in T and B cell responses to drug antigens. Allergy. 2022;77(4):1129-1138.
Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract. 2016;4(3):497-504.
Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159-170 e2.
Carroll-Portillo A, Spendier K, Pfeiffer J, et al. Formation of a mast cell synapse: FcεRI membrane dynamics upon binding mobile or immobilized ligands on surfaces. J Immunol. 2010;184(3):1328-1338.
Dona I, Caubet JC, Brockow K, et al. An EAACI task force report: Recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity. Clin Transl Allergy. 2018;8:16.
Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-712.
Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47-52.
Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy. 2011;66(2):247-254.
Gamboa PM, Sanz ML, Caballero MR, et al. Use of CD63 expression as a marker ofin vitrobasophil activation and leukotriene determination in metamizol allergic patients. Allergy. 2003;58(4):312-317.
Leysen J, Bridts CH, De Clerck LS, et al. Allergy to rocuronium: from clinical suspicion to correct diagnosis. Allergy. 2011;66(8):1014-1019.
Ariza A, Mayorga C, Bogas G, et al. Detection of serum-specific IgE by fluoro-enzyme immunoassay for diagnosing type I hypersensitivity reactions to penicillins. Int J Mol Sci. 2022;23:13.
Kalangara J, Potru S, Kuruvilla M. Clinical manifestations and diagnostic evaluation of opioid allergy labels - a review. J Pain Palliat Care Pharmacother. 2019;33(3-4):131-140.
Opstrup MS, Jemec GBE, Garvey LH. Chlorhexidine allergy: on the rise and often overlooked. Curr Allergy Asthma Rep. 2019;19(5):23.
Park KH, Lee J, Beom SH, et al. Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection. World Allergy Organ J. 2021;14(7):100553.
Pena-Mendizabal E, Morais S, Maquieira A. Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam. Sci Rep. 2020;10(1):16037.
Martin-Serrano A, Mayorga C, Barrionuevo E, et al. Design of an antigenic determinant of cefaclor: chemical structure-IgE recognition relationship. J Allergy Clin Immunol. 2020;145(4):1301-1304.e4.
Barbero N, Fernandez-Santamaria R, Mayorga C, et al. Identification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactions. Allergy. 2019;74(8):1490-1501.
Fernandez-Santamaria R, Bogas G, Montanez MI, et al. Synthetic antigenic determinants of clavulanic acid induce dendritic cell maturation and specific T cell proliferation in patients with immediate hypersensitivity reactions. Allergy. 2022;77(10):3070-3083.
Ariza A, Jaruthamsophon K, Meng X, et al. Shared clavulanate and tazobactam antigenic determinants activate T-cells from hypersensitive patients. Chem Res Toxicol. 2022;35(11):2122-2132.
Quintero-Campos P, Segovia-de Los Santos P, Ibanez-Echevarria E, et al. An ultra-sensitive homologous chemiluminescence immunoassay to tackle penicillin allergy. Anal Chim Acta. 2022;1214:339940.
Juarez MJ, Ibanez-Echevarria E, de Rojas DH, Maquieira A, Morais S. Multiplexed analytical approaches to beta-lactam allergy in vitro testing standardization. Anal Chim Acta. 2021;1173:338656.
Gil-Ocaña V, Jimenez IM, Mayorga C, et al. Multiepitope dendrimeric antigen-silica particle composites as Nano-based platforms for specific recognition of IgEs. Front Immunol. 2021;12:750109.
Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2020;75(6):1300-1315.
Céspedes JA, Fernández-Santamaría R, Ariza A, et al. Diagnosis of immediate reactions to amoxicillin: Comparison of basophhil activation markers CD63 and CD203c in a prospective study. Allergy. 2023;78(10):2745-2755.
Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy. 2008;38(6):921-928.
Heremans K, Toscano A, Elst J, et al. Basophil activation test shows poor sensitivity in immediate amoxicillin allergy. J Allergy Clin Immunol Pract. 2023;11(2):500-505.
Montanez MI, Mayorga C, Bogas G, et al. Epidemiology, mechanisms, and diagnosis of drug-induced anaphylaxis. Front Immunol. 2017;8:614.
Miura K, MacGlashan DW. Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils. Blood. 2000;96(6):2199-2205.
Jonsson F, de Chaisemartin L, Granger V, et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci Transl Med. 2019;11(500):eaat1479.
Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol. 2009;393(3):598-607.
Pennington LF, Gasser P, Brigger D, Guntern P, Eggel A, Jardetzky TS. Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions. J Allergy Clin Immunol. 2021;148(4):1049-1060.
Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun. 2016;7:11610.
Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
Mackay GA, Fernandopulle NA, Ding J, McComish J, Soeding PF. Antibody or anybody? Considering the role of MRGPRX2 in acute drug-induced anaphylaxis and as a therapeutic target. Front Immunol. 2021;12:688930.
Fernández TD, Torres MJ, Blanca-López N, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy. 2009;64(2):242-248.
Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy. 2006;61(3):311-315.
Ariza A, Torres MJ, Moreno-Aguilar C, Fernández-Santamaría R, Fernández TD. Early biomarkers for severe drug hypersensitivity reactions. Curr Pharm Des. 2019;25(36):3829-3839.
Ebo DG, Van Gasse AL, Decuyper II, et al. Acute management, diagnosis, and follow-up of suspected perioperative hypersensitivity reactions in Flanders 2001-2018. J Allergy Clin Immunol Pract. 2019;7(7):2194-2204.e7.
Vitte J, Amadei L, Gouitaa M, et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: an observational study. Allergy. 2019;74(6):1157-1165.
Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983;309(26):1603-1605.
Keyzer JJ, Breukelman H, Wolthers BG, van den Heuvel M, Kromme N, Berg WC. Urinary excretion of histamine and some of its metabolites in man: influence of the diet. Agents Actions. 1984;15(3-4):189-194.
Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol. 2009;124(4):639-646; quiz 647-8.
Mayorga C, Muñoz-Cano R, Rodríguez-Nogales A, Fernández-Santamaría R, Fernández T. New insights of biomarkers in IgE and Non-IgE-mediated drug hypersensitivity. Curr Treat Options Allergy. 2019;6:42-55.
Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120(3):506-515; quiz 516-7.
Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci USA. 2011;108(30):12413-12418.
Munoz-Cano R, Pascal M, Bartra J, et al. Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. J Allergy Clin Immunol. 2016;137(1):137-146.
Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358(1):28-35.
Gill P, Jindal NL, Jagdis A, Vadas P. Platelets in the immune response: revisiting platelet-activating factor in anaphylaxis. J Allergy Clin Immunol. 2015;135(6):1424-1432.
MacGlashan D Jr, White JM, Huang SK, Ono SJ, Schroeder JT, Lichtenstein LM. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol. 1994;152(6):3006-3016.
Zwirner J, Gotze O, Sieber A, et al. The human mast cell line HMC-1 binds and responds to C3a but not C3a(desArg). Scand J Immunol. 1998;47(1):19-24.
Gabizon A, Szebeni J. Complement activation: a potential threat on the safety of poly(ethylene glycol)-coated nanomedicines. ACS Nano. 2020;14(7):7682-7688.
Kozma GT, Meszaros T, Vashegyi I, et al. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano. 2019;13(8):9315-9324.
Hempel JC, Poppelaars F, Gaya da Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017;45(1):49-59.
Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11(3):262-268.
Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159-170.e2.
McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237-241.
Sabato V, Elst J, Van Houdt M, Bridts C, Mertens C, Ebo DG. Surface expression of MRGPRX2 on resting basophils: an area of controversy. Allergy. 2020;75(9):2421-2422.
Sabato V, Ebo DG, Van Der Poorten MM, et al. Allergenic and mas-related G protein-coupled receptor X2-activating properties of drugs: resolving the two. J Allergy Clin Immunol Pract. 2023;11(2):395-404.
Babina M, Wang Z, Li Z, et al. FcεRI- and MRGPRX2-evoked acute degranulation responses are fully additive in human skin mast cells. Allergy. 2022;77(6):1906-1909.
Gaudenzio N, Sibilano R, Marichal T, et al. Different activation signals induce distinct mast cell degranulation strategies. J Clin Invest. 2016;126(10):3981-3998.
Vitte J, Sabato V, Tacquard C, et al. Use and interpretation of acute and baseline tryptase in perioperative hypersensitivity and anaphylaxis. J Allergy Clin Immunol Pract. 2021;9(8):2994-3005.
Elst J, van der Poorten MM, Van Gasse AL, et al. Tryptase release does not discriminate between IgE- and MRGPRX2-mediated activation in human mast cells. Clin Exp Allergy. 2022;52(6):797-800.
Ebo DG, Van der Poorten ML, Elst J, et al. Immunoglobulin E cross-linking or MRGPRX2 activation: clinical insights from rocuronium hypersensitivity. Br J Anaesth. 2021;126(1):e27-e29.
Ebo DG, Heremans K, Beyens M, et al. Flow-based allergen testing: can mast cells beat basophils? Clin Chim Acta. 2022;532:64-71.
Lafleur MA, Werner J, Fort M, Lobenhofer EK, Balazs M, Goyos A. MRGPRX2 activation as a rapid, high-throughput mechanistic-based approach for detecting peptide-mediated human mast cell degranulation liabilities. J Immunotoxicol. 2020;17(1):110-121.
Elst J, Sabato V, Faber MA, et al. MRGPRX2 and immediate drug hypersensitivity: insights from cultured human mast cells. J Investig Allergol Clin Immunol. 2021;31(6):489-499.
Kumar M, Duraisamy K, Chow BK. Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2). Cell. 2021;10:5.
Haque R, White AA, Jackson DJ, Hopkins C. Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148(2):283-291.
Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: A UK cohort study. Lancet Respir Med. 2015;3(11):849-858.
Alahmadi F, Peel A, Keevil B, Niven R, Fowler SJ. Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: a literature review. Clin Exp Allergy. 2021;51(1):49-62.
Ulrik CS, Lange P, Hilberg O. Fractional exhaled nitric oxide as a determinant for the clinical course of asthma: a systematic review. Eur Clin Respir J. 2021;8(1):1891725.
Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in teh LIBERTY ASTHMA QUEST study: A post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
Jakiela B, Soja J, Sladek K, et al. Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147(4):1269-1280.
Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020;125(2):171-176.
Alving K, Diamant Z, Lucas S, et al. Point-of-care biomarkers in asthma management: time to move forward. Allergy. 2020;75(4):995-997.
Buchheit KM, Dwyer DF, Ordovas-Montanes J, et al. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2020;145(6):1574-1584.
Izuhara K, Nunomura S, Nanri Y, Ono J, Takai M, Kawaguchi A. Periostin: an emerging biomarker for allergic diseases. Allergy. 2019;74(11):2116-2128.
Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835-1851.
Bangert C, Villazala-Merino S, Fahrenberger M, et al. Comprehensive analysis of nasal polyps reveals a more pronounced type 2 transcriptomic profile of epithelial cells and mast cells in aspirin-exacerbated respiratory disease. Front Immunol. 2022;13:850494.
Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med. 2015;192(6):682-694.
Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2013;132(4):856-865.e1-3.
Choi Y, Sim S, Lee DH, et al. Effect of TGF-β1 on eosinophils to induce cysteinyl leukotriene E4 production in aspirin-exacerbated respiratory disease. PLoS One. 2021;16(8):e0256237.
Sim S, Choi Y, Lee DH, Lee HR, Seob Shin Y, Park HS. Contribution of dipeptidyl peptidase 10 to airway dysfunction in patients with NSAID-exacerbated respiratory disease. Clin Exp Allergy. 2022;52(1):115-126.
Choi Y, Lee DH, Trinh HKT, et al. Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease. Allergy. 2019;74(1):78-88.
Trinh HKT, Pham DL, Choi Y, Kim HM, Kim SH, Park HS. Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease. Clin Exp Allergy. 2018;48(11):1464-1473.
Dona I, Perez-Sanchez N, Bogas G, Moreno E, Salas M, Torres MJ. Medical algorithm: diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity. Allergy. 2020;75(4):1003-1005.
Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD) - a EAACI position paper. Allergy. 2019;74(1):28-39.
Ban GY, Kim SH, Park HS. Persistent eosinophilic inflammation in adult asthmatics with high serum and urine levels of leukotriene E4. J Asthma Allergy. 2021;14:1219-1230.
Mastalerz L, Celejewska-Wojcik N, Wojcik K, et al. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. Allergy. 2014;69(11):1550-1559.
Jakiela B, Soja J, Sladek K, et al. Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;147(4):1269-1280.
Celejewska-Wojcik N, Wojcik K, Ignacak-Popiel M, et al. Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis. Allergy. 2020;75(4):831-840.
Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol. 1999;104(3 Pt 1):559-564.
Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol. 2003;139(12):1577-1582.
Dona I, Jurado-Escobar R, Perkins JR, et al. Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria. Allergy. 2019;74(6):1135-1144.
Klaewsongkram J, Buranapraditkun S, Mongkolpathumrat P, Palapinyo S, Chantaphakul H. Clinical characteristics, urinary leukotriene E4 levels, and aspirin desensitization results in patients with NSAID-induced blended reactions. Allergy Asthma Immunol Res. 2021;13(2):229-244.
Oussalah A, Mayorga C, Blanca M, et al. Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review. Allergy. 2016;71(4):443-462.
Garcia-Martin E, Garcia-Menaya JM, Esguevillas G, et al. Deep sequencing of prostaglandin-endoperoxide synthase (PTGE)genes reveals genetic susceptibility for cross-reactive hypersensitivity to NSAID. Br J Pharmacol. 2021;178(5):1218-1233.
Jurado-Escobar R, Dona I, Perkins JR, et al. Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity. Br J Dermatol. 2021;185(4):815-824.
Jurado-Escobar R, Dona I, Triano-Cornejo J, et al. Genetic variants in cytosolic phospholipase A2 associated with nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema. Front Pharmacol. 2021;12:667824.
Wood SM, Mann RD, Rawlins MD. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J (Clin Res ed). 1987;294(6564):91-92.
Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep. 2003;5(4):346-352.
Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24(8):599-606.
Jeon J, Lee YJ, Lee SY. Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2019;44(5):685-692.
Porebski G, Kwitniewski M, Reshef A. Biomarkers in hereditary angioedema. Clin Rev Allergy Immunol. 2021;60(3):404-415.
Manning ME. Hereditary angioedema: differential diagnosis, diagnostic tests, and family screening. Allergy Asthma Proc. 2020;41(Suppl 1):S22-S25.
Hahn J, Nordmann-Kleiner M, Bonner C, Kojda G, Hoffmann TK, Greve J. The influence of ACE inhibition on C1-inhibitor: a biomarker for ACE inhibitor-induced angioedema? Biomed Hub. 2019;4(2):1-9.
Bas M, Hoffmann TK, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol. 2005;59(2):233-238.
Ferreira TA, Alves MR, Oliveira AMP, Silva FSS, Pereira C. A rare cause of abdominal pain: intestinal angioedema. J Med Cases. 2021;12(4):138-140.
Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema. Hypertension. 2008;51(1):141-147.
Bindke G, Gehring M, Wieczorek D, Kapp A, Buhl T, Wedi B. Identification of novel biomarkers to distinguish bradykinin-mediated angioedema from mast cell-/histamine-mediated angioedema. Allergy. 2022;77(3):946-955.
Bas M, Storck K, Strassen U. Potential biomarkers for the diagnosis of angiotensin-converting enzyme inhibitor-induced angioedema. ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):85-92.